8,100 Shares in Nuvalent, Inc. $NUVL Acquired by Artia Global Partners LP

Artia Global Partners LP acquired a new position in shares of Nuvalent, Inc. (NASDAQ:NUVL) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 8,100 shares of the company’s stock, valued at approximately $815,000.

Several other institutional investors have also recently modified their holdings of the stock. GAMMA Investing LLC raised its position in shares of Nuvalent by 47.6% during the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock worth $34,000 after purchasing an additional 108 shares during the last quarter. Kennedy Capital Management LLC raised its position in shares of Nuvalent by 1.5% during the 4th quarter. Kennedy Capital Management LLC now owns 10,932 shares of the company’s stock worth $1,100,000 after purchasing an additional 163 shares during the last quarter. US Bancorp DE raised its position in shares of Nuvalent by 10.0% during the 3rd quarter. US Bancorp DE now owns 2,070 shares of the company’s stock worth $179,000 after purchasing an additional 188 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of Nuvalent by 7.7% during the 3rd quarter. Principal Financial Group Inc. now owns 3,290 shares of the company’s stock worth $285,000 after purchasing an additional 234 shares during the last quarter. Finally, Guggenheim Capital LLC raised its position in shares of Nuvalent by 2.7% during the 2nd quarter. Guggenheim Capital LLC now owns 10,863 shares of the company’s stock worth $829,000 after purchasing an additional 288 shares during the last quarter. 97.26% of the stock is currently owned by institutional investors and hedge funds.

Nuvalent Stock Down 0.0%

Shares of NASDAQ NUVL opened at $123.36 on Thursday. Nuvalent, Inc. has a 52-week low of $71.13 and a 52-week high of $123.62. The firm has a fifty day moving average of $105.32 and a 200-day moving average of $103.71. The stock has a market capitalization of $9.75 billion, a PE ratio of -20.36 and a beta of 1.15.

Nuvalent (NASDAQ:NUVL) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same quarter in the prior year, the firm earned ($1.18) EPS. Equities research analysts expect that Nuvalent, Inc. will post -5.74 EPS for the current fiscal year.

Insider Buying and Selling at Nuvalent

In related news, insider Deborah Ann Miller sold 5,500 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $107.84, for a total transaction of $593,120.00. Following the completion of the sale, the insider directly owned 59,634 shares of the company’s stock, valued at approximately $6,430,930.56. This represents a 8.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Henry E. Pelish sold 3,093 shares of the company’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $104.48, for a total transaction of $323,156.64. Following the sale, the insider directly owned 65,604 shares of the company’s stock, valued at approximately $6,854,305.92. This trade represents a 4.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 126,953 shares of company stock valued at $12,612,264 in the last quarter. Company insiders own 5.02% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on NUVL. Stifel Nicolaus set a $124.00 price target on Nuvalent in a report on Tuesday, June 9th. Robert W. Baird set a $122.85 price target on Nuvalent in a report on Tuesday, June 9th. Piper Sandler downgraded Nuvalent from an “overweight” rating to a “neutral” rating and set a $124.00 price target for the company. in a report on Tuesday, June 9th. Wedbush downgraded Nuvalent from an “outperform” rating to a “neutral” rating and cut their price target for the company from $125.00 to $124.00 in a report on Tuesday, June 9th. Finally, UBS Group downgraded Nuvalent from a “buy” rating to a “neutral” rating and cut their price target for the company from $138.00 to $124.00 in a report on Wednesday, June 10th. Five investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Nuvalent presently has a consensus rating of “Hold” and a consensus target price of $131.15.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.